AU2001261171A1 - Compounds and methods for the treatment and prevention of bacterial infection - Google Patents

Compounds and methods for the treatment and prevention of bacterial infection

Info

Publication number
AU2001261171A1
AU2001261171A1 AU2001261171A AU6117101A AU2001261171A1 AU 2001261171 A1 AU2001261171 A1 AU 2001261171A1 AU 2001261171 A AU2001261171 A AU 2001261171A AU 6117101 A AU6117101 A AU 6117101A AU 2001261171 A1 AU2001261171 A1 AU 2001261171A1
Authority
AU
Australia
Prior art keywords
moiety
mutant
pore
mutation
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261171A
Other languages
English (en)
Inventor
R. John Collier
Bret R. Sellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of AU2001261171A1 publication Critical patent/AU2001261171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001261171A 2000-05-04 2001-05-04 Compounds and methods for the treatment and prevention of bacterial infection Abandoned AU2001261171A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20180000P 2000-05-04 2000-05-04
US60201800 2000-05-04
PCT/US2001/014372 WO2001082788A2 (fr) 2000-05-04 2001-05-04 Traitement et prevention d'infections bacteriennes et composes a cet effet

Publications (1)

Publication Number Publication Date
AU2001261171A1 true AU2001261171A1 (en) 2001-11-12

Family

ID=22747352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261171A Abandoned AU2001261171A1 (en) 2000-05-04 2001-05-04 Compounds and methods for the treatment and prevention of bacterial infection

Country Status (15)

Country Link
US (1) US7037503B2 (fr)
EP (1) EP1278764A4 (fr)
JP (1) JP2003531841A (fr)
KR (1) KR20030019366A (fr)
CN (1) CN1440419A (fr)
AU (1) AU2001261171A1 (fr)
CA (1) CA2407443A1 (fr)
CZ (1) CZ20023662A3 (fr)
HU (1) HUP0301658A2 (fr)
IL (1) IL152553A0 (fr)
MX (1) MXPA02010826A (fr)
NO (1) NO20025204L (fr)
PL (1) PL365453A1 (fr)
WO (1) WO2001082788A2 (fr)
ZA (1) ZA200208835B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
AU2002239229A1 (en) 2000-12-05 2002-06-18 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
US7763451B2 (en) 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines
JP2005511059A (ja) * 2001-12-05 2005-04-28 バートナガー ラケシュ 非毒性炭疽ワクチンの調製のためのプロセス
AU2003213022A1 (en) * 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
US20040258699A1 (en) * 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
EP1530634A4 (fr) 2002-06-26 2005-11-02 Human Genome Sciences Inc Sequences shine-dalgarno et procedes d'utilisation
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
AU2003304316A1 (en) * 2002-11-08 2005-01-28 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
JP4545151B2 (ja) * 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
US20080206276A1 (en) * 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
AU2007259329A1 (en) * 2006-05-12 2007-12-21 Farris, Darise Anthrax compositions and methods of use and production
WO2009126355A2 (fr) * 2008-01-28 2009-10-15 Baxter International, Inc. Procédés d’augmentation de la production recombinante de l’antigène protecteur de bacillus anthracis
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5591631A (en) 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
EP0866718A1 (fr) 1995-12-13 1998-09-30 President And Fellows Of Harvard College Utilisation de peptides de toxine et/ou de marqueurs d'affinite pour l'introduction de composes dans des cellules
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
AU2771099A (en) 1998-02-18 1999-09-06 President And Fellows Of Harvard College Inhibition of toxin translocation
US6426231B1 (en) * 1998-11-18 2002-07-30 The Texas A&M University System Analyte sensing mediated by adapter/carrier molecules
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis

Also Published As

Publication number Publication date
ZA200208835B (en) 2004-02-09
CZ20023662A3 (cs) 2003-04-16
EP1278764A2 (fr) 2003-01-29
CN1440419A (zh) 2003-09-03
HUP0301658A2 (hu) 2003-08-28
NO20025204D0 (no) 2002-10-30
WO2001082788A2 (fr) 2001-11-08
US20020039588A1 (en) 2002-04-04
PL365453A1 (en) 2005-01-10
WO2001082788A3 (fr) 2002-07-25
KR20030019366A (ko) 2003-03-06
WO2001082788A9 (fr) 2002-12-19
NO20025204L (no) 2002-12-16
IL152553A0 (en) 2003-05-29
EP1278764A4 (fr) 2004-05-19
CA2407443A1 (fr) 2001-11-08
JP2003531841A (ja) 2003-10-28
US7037503B2 (en) 2006-05-02
MXPA02010826A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
US7037503B2 (en) Compounds and methods for the treatment and prevention of bacterial infection
US8067015B2 (en) Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US8883172B2 (en) Chemically modified peptides with improved immunogenicity
AU2006257774B2 (en) Use of Panton-Valentine Leukocidin for treating and preventing Staphylococcus infections
KR20130093084A (ko) 단백질 A(SpA) 변이체와 관련된 조성물 및 방법
JP6084631B2 (ja) Clostridiumdifficile毒素ベースのワクチン
KR20120034612A (ko) 황색 포도상구균에 대한 면역화를 위한 조성물
EP1037650B1 (fr) Compositions pour le traitement d'infections a staphylococcus aureus
US20140302084A1 (en) Immunogenic protein conjugates and method for making and using the same
US7901692B2 (en) Nontypeable Haemophilus influenzae virulence factors
JP2021506824A (ja) ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
König et al. Multi-antigen outer membrane vesicle engineering to develop polyvalent vaccines: the Staphylococcus aureus case
EP3758744B1 (fr) Toxine epsilon provenant de clostridium perfringens en tant que vaccin
US20080152701A1 (en) Methods and Compositions for the Treatment and Prevention of Staphylococcus Infections
KR100509712B1 (ko) 나이세리아 락토페린 결합 단백질
WO2005004791A2 (fr) Composes et procedes de traitement et de prevention d'infections bacteriennes
US20090123458A1 (en) Protective Antigen Having Fluorinated Histidine Residues
EP1980267A1 (fr) Protéine de transcytosis de pneumonie S
WO2005023851A1 (fr) Polypeptides de liaison au plasminogene/a la plasmine et acides nucleiques associes
Himanen et al. The 20 kDa C-terminally truncated form of pertussis toxin subunit S1 secreted from Bacillus subtilis
Caproni et al. Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: The
Xu Analyses of structure-function properties and entry mechanism of pertussis toxin
JPH1169982A (ja) 新規Div1b
EP1904520A2 (fr) Vaccin contre les infections staphylococciques